MerolaJF, SidburyR, WollenbergA, et al.Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial. J Am Acad Dermatol. 2021; 84:495–497.
2.
BlauveltA, Guttman-YasskyE, PallerAS, et al.Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022; 23:365–383.
3.
PotestioL, NapolitanoM, BennardoL, et al.Atopic dermatitis exacerbation after Covid-19 vaccination in Dupilumab-treated patients. J Eur Acad Dermatol Venereol. 2022; 36:e409–411.
4.
PouraniMR, GanjiR, DashtiT, et al.Impact of COVID-19 pandemic on patients with atopic dermatitis. Actas Dermosifiliogr. 2022; 113:286–293.
5.
TangTS, BieberT, WilliamsHC. Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful?. J Allergy Clin Immunol. 2014; 133:1615–1625 e1611.
6.
RussoF, CioppaV, CartocciA, et al.Dupilumab and atopic dermatitis flares: an observational study to identify common clinical features in patients who have exacerbations despite biological therapy. Dermatitis. In Press; 2023.
